Table.
Summary of the 36 Patients With Generalized Myasthenia Gravis (MG) Being Treated With Efgartigimod
| Age, y | 53.0 ± 14.7 |
| Female, n (%) | 25 (68) |
| Disease duration, y | 12.9 ± 14.7 |
| MG subtype, n (%) | |
| AChR+ early onset | 4 (11) |
| AChR+ late onset | 5 (14) |
| AChR+ thymoma associated | 10 (28) |
| MuSK+ | 6 (17) |
| Seronegative | 11 (31) |
| Worst MGFA classification, n (%) | |
| II, mild | 4 (11) |
| III, moderate | 19 (53) |
| IV, severe | 8 (22) |
| V, crisis | 5 (14) |
| Worst quantitative MG score | 18.9 ± 6.3 |
| Oral prednisolone | 33 (92) |
| Calcineurin inhibitors | 35 (97) |
| Thymectomy | |
| Thymectomy for thymoma | 10/10 (100%) |
| Thymectomy for non-thymoma | 6/26 (23%) |
| Fast-acting treatment, n (%) | |
| Plasmapheresis | 26 (72) |
| Intravenous immunoglobulin | 26 (72) |
| Intravenous high-dose methylprednisolone | 28 (78) |
| Molecular targeting drugs, n (%) | |
| Rituximab | 2 (6) |
| Eculizumab | 5 (14) |
| MG status, n (%) | |
| Minimal manifestations or better | 0 (0) |
| Refractory | 26 (72) |
Abbreviations: AChR+ = anti–acetylcholine receptor–positive; MG = myasthenia gravis; MGFA = MG Foundation of America; MuSK+ = anti–muscle-specific receptor tyrosine kinase–positive.